-
1.发明公开SALT AND POLYMORPH OF PYRAZOLOPYRIMIDINONE COMPOUND AND DRUG COMPOSITION, PREPARATION METHOD AND USE THEREOF 有权盐和多晶型吡唑并嘧啶和活性物质，其制造方法相同，它们的用途
公开(公告)号：EP2746284A4
公开(公告)日：2015-01-14
申请号：EP12823704
申请日：2012-08-14
发明人： LI JIANFENG , TIAN GUANGHUI , WANG ZHEN , SUO JIN , JIANG XIANGRUI , LIU ZHENG , YANG XIAOJUN , XIE ZHU , ZHAO XIANGUO , ZHU WEILIANG , JIANG HUALIANG , SHEN JINGSHAN
IPC分类号： C07D487/04 , A61K31/519 , A61P1/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/00 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/00 , A61P15/06 , A61P15/10 , A61P25/00 , A61P27/06 , A61P29/00 , A61P37/08
CPC分类号： C07D487/04 , C07B2200/13
摘要： The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.
-
2.发明公开PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF 有权PHENYLPYRIMIDONVERBINDUNGEN，药物组合物，方法和应用
公开(公告)号：EP2383262A4
公开(公告)日：2012-10-31
申请号：EP09831388
申请日：2009-12-10
发明人： LIU ZHENG , LI JIANFENG , YANG XIAOJUN , WANG ZHEN , ZHANG JINFENG , ZHU YI , TIAN GUANGHUI , JIN QING , SHEN JINGKANG , ZHU WEILIANG , JIANG HUALIANG , SHEN JINGSHAN
IPC分类号： C07D239/36 , A61K31/505 , A61P15/10
CPC分类号： A61K31/505 , C07D239/36 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07H15/26
-
3.发明公开HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF 审中-公开混合动力学VERBINDUNGEN UND HERSTELLUNGSVERFAHREN UND VERWENDUNG DAVON
公开(公告)号：EP3115361A4
公开(公告)日：2017-04-26
申请号：EP15757771
申请日：2015-03-09
申请人： SHANGHAI INST MATERIA MEDICA CAS , SUZHOU VIGONVITA LIFE SCIENCES CO LTD , TOPHARMAN SHANDONG CO LTD
发明人： JIANG HUALIANG , WANG ZHEN , LI JIANFENG , ZHANG RONGXIA , HE YANG , LIU YONGJIAN , BI MINGHAO , LIU ZHENG , TIAN GUANGHUI , CHEN WEIMING , YANG FEIPU , WU CHUNHUI , WANG YU , JIANG XIANGRUI , YIN JINGJING , WANG GUAN , SHEN JINGSHAN
IPC分类号： C07D409/12 , A61K31/4709 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/538 , A61K31/5415 , A61K31/55 , A61P25/00 , A61P25/18 , A61P25/22 , A61P25/24 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04 , C07D519/00
CPC分类号： C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04 , C07D519/00
摘要： Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation of a drug for the prevention and/or treatment of a central nervous system disease.
摘要翻译： 提供由式（I）表示的杂环化合物，所述化合物的立体异构体或药学上可接受的盐，所述化合物的药物组合物，以及所述化合物在制备用于预防和/或治疗中枢神经系统 系统疾病。
-
4.发明公开HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 审中-公开[HEXAHYDRODIBENZO- [A，G]喹CONNECTION，METHOD FOR THE PRODUCTION，药物组合物和正确使用
公开(公告)号：EP2716640A4
公开(公告)日：2014-04-09
申请号：EP12793899
申请日：2012-04-09
发明人： LIU HONG , ZHEN XUECHU , SUN HAIFENG , ZHU LIYUAN , LI ZENG , JIANG HUALIANG , CHEN KAIXIAN , XIE XIN , LI JING , CHEN YING
IPC分类号： C07D455/03 , A61K31/4375 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/30
CPC分类号： C07D491/153 , C07C69/736 , C07C231/14 , C07D217/20 , C07D311/20 , C07D455/03 , C07D491/056 , C07D491/147 , C07D491/22
摘要： The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.
-
5.发明公开1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 审中-公开1-（3-氨基丙醇）取代基环戊二烯腈，HERSTELLUNGSVERFAHRENDAFÜRUND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON
公开(公告)号：EP3091013A4
公开(公告)日：2017-06-07
申请号：EP14877091
申请日：2014-12-29
发明人： LIU HONG , WU BEILI , ZHENG YONGTANG , XIE XIN , JIANG HUALIANG , PENG PANFENG , LUO RONGHUA , LI JING , LI JIAN , ZHU YA , CHEN YING , ZHANG HAONAN , YANG LIUMENG , ZHOU YU , CHEN KAIXIAN
IPC分类号： C07D409/14 , A61K31/454 , A61K31/4545 , A61K31/46 , A61P31/18 , C07D401/14 , C07D451/04 , C07D519/00
CPC分类号： C07D519/00 , A61K31/454 , A61K31/4545 , A61K31/46 , A61K45/06 , C07D401/14 , C07D409/14 , C07D451/04 , A61K2300/00
摘要： Provided are 1-(3-aminopropyl) substituted cyclic amine compounds as represented by formula (I), pharmaceutically acceptable salts, enantiomers, diastereoisomers, racemates and mixtures thereof, and a method of synthesizing said 1-(3-aminopropyl) substituted cyclic amine compounds by using aromatic heterocyclic formaldehyde as raw material. Said compounds can be used as CCR 5 antagonist for the treatment of HIV infection.
摘要翻译： 提供式（I）所示的1-（3-氨基丙基）取代环胺化合物，其药学上可接受的盐，对映体，非对映异构体，外消旋体及其混合物，以及合成所述1-（3-氨基丙基）取代的环胺 化合物以芳香族杂环甲醛为原料。 所述化合物可以用作治疗HIV感染的CCR5拮抗剂。
-
6.发明公开COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME 审中-公开接线7元环和它们的药物用于预防和糖尿病和代谢综合征的治疗
公开(公告)号：EP2199295A4
公开(公告)日：2011-01-05
申请号：EP07721682
申请日：2007-05-29
发明人： SHEN JIANHUA , LENG YING , JIANG HUALIANG , CHEN JUNHUA
IPC分类号： C07D513/14 , A61K31/55 , A61K31/5513 , A61K31/553 , A61K31/554 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P43/00 , C07D243/38 , C07D321/10 , C07D487/04 , C07D487/14 , C07D493/14 , C07D495/14 , C07D497/14 , C07D498/14
CPC分类号： C07D243/38 , C07D243/14 , C07D267/20 , C07D281/16 , C07D321/10 , C07D405/12 , C07D487/04 , C07D487/14 , C07D493/14 , C07D495/14 , C07D497/14 , C07D498/14 , C07D513/14
-
7.发明公开METHODS AND COMPOSITIONS FOR INHIBITING HUMAN COPPER TRAFFICKING PROTEINS ATOX1 AND CCS 审中-公开方法和组合物用于抑制人贩卖铜蛋白和ATOX1 CCS
公开(公告)号：EP2948438A4
公开(公告)日：2016-10-05
申请号：EP14742923
申请日：2014-01-23
IPC分类号： C07D333/00 , A61K31/4365 , A61P35/00 , C07D471/14
CPC分类号： A61K31/4365 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/444 , A61K31/4741 , A61K31/4743 , A61K45/06 , C07D491/048 , C07D491/147 , C07D495/04 , C07D495/14 , A61K2300/00
-
8.发明公开FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF 有权FLUOR取代的环胺类化合物和方法，以及其使用的药物组合物
公开(公告)号：EP2913324A4
公开(公告)日：2016-03-30
申请号：EP13849440
申请日：2013-10-17
发明人： LIU HONG , ZHANG HAIYAN , ZHOU YU , FU YAN , JIANG HUALIANG , TANG XICAN , CHEN KAIXIAN
IPC分类号： C07D211/38 , A61K31/445 , A61K31/4525 , A61K31/46 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/28 , C07D405/06 , C07D451/04
CPC分类号： C07D211/32 , A61K45/06 , C07D211/34 , C07D211/38 , C07D405/06 , C07D451/04 , C07D471/08 , C07D491/107
摘要： The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular to compounds of general formula I, racemates, R-isomers, S-isomers, and pharmaceutically acceptable salts thereof and their mixtures, and the preparation methods thereof and a pharmaceutical composition containing the compounds and uses thereof as an acetylcholine esterase inhibitor.
摘要翻译： 本发明涉及药物化学和Pharmacotherapeutics的领域，并且特别是它们的混合物和通式I，种族匹配，R异构体，S-异构体，以及它们的药学上可接受的盐的化合物和，以及它们的制备方法的药物 含有该组合物的化合物和它们的用途如乙酰胆碱酯酶抑制剂。
-
9.发明公开DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF 审中-公开DIARYL [A，G-] CHINOLIZIDINVERBINDUNG，HERSTELLUNGSVERFAHRENDAFÜR，PHARMAZEUTISCHE ZUSAMMENSETZUNG UND VERWENDUNGEN DAVON
公开(公告)号：EP2848617A4
公开(公告)日：2015-03-18
申请号：EP13787305
申请日：2013-05-09
发明人： LIU HONG , ZHEN XUECHU , SUN HAIFENG , ZHU LIYUAN , QIAN WANGKE , YU LEIPING , LI ZENG , ZHOU SHENGBIN , CAI WENXIAN , JIANG HUALIANG , CHEN KAIXIAN
IPC分类号： C07D455/03 , A61K31/4375 , A61P25/00 , A61P25/18
CPC分类号： C07D471/14 , C07D455/03 , C07D491/147 , C07D491/22 , C07D495/14 , C07D495/22
摘要： The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.
摘要翻译： 本发明涉及式（I）的二异丙基[a，g]喹嗪啶化合物，其对映异构体，非对映异构体，外消旋体，混合物，药学上可接受的盐，结晶水合物或其溶剂化物; 其制备方法及其在制备与多巴胺受体和5-HT受体相关的实验模型药物中的用途，或其用于治疗或预防与多巴胺受体和5-HT受体有关的疾病的药物。
-
公开(公告)号：EP3257856A4
公开(公告)日：2018-07-25
申请号：EP16748699
申请日：2016-02-03
发明人： LIU HONG , WANG JIAN , LI JIAN , LI JIA , LI JINGYA , ZHOU SHENGBIN , SU MINGBO , JIANG HUALIANG , LUO XIAOMIN , CHEN KAIXIAN
IPC分类号： C07D495/04 , A61K31/519 , A61P3/10
CPC分类号： C07D495/04 , A61K31/519 , C07B2200/13
摘要： The present invention relates to crystal form A of a compound. The present invention also discloses a preparation method and a pharmaceutical composition of the crystal form A. The crystal form A has strong hypoglycemic activity in vivo and is expected to be a novel pharmaceutically active ingredient for treating or preventing type II diabetes and/or complications of type II diabetes.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.013 秒)
